Chimeric receptors with 4-1BB stimulatory signaling domain
AssigneeSt. Jude Children's Research Hospital
InventorsDario Campana, Chihaya Imai
Life of this patent
Estimating the term…
Abstract
The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
Claims22
A polynucleotide encoding a chimeric receptor comprising:
- (a) an extracellular ligand-binding domain comprising an anti-CD19 single chain variable fragment (scFv) domain;
- (b) a transmembrane domain;
- and (c) a cytoplasmic domain comprising a 4-1BB signaling domain and a CD3ζ signaling domain.
A vector comprising a polynucleotide encoding a chimeric receptor comprising:
- (a) an extracellular ligand-binding domain comprising an anti-CD19 single chain variable fragment (scFv) domain, (b) a transmembrane domain, and (c) a cytoplasmic domain comprising a 4-1BB signaling domain and a CD3ζ signaling domain, wherein the polynucleotide encoding the chimeric receptor is operatively linked to at least one regulatory element for expression of the chimeric receptor.
An isolated host cell comprising a polynucleotide encoding a chimeric receptor comprising:
- (a) an extracellular ligand-binding domain comprising an anti-CD19 single chain variable fragment (scFv) domain;
- (b) a transmembrane domain;
- and (c) a cytoplasmic domain comprising a 4-1BB signaling domain and a CD3ζ signaling domain.
Dependencies are inferred from the claim text.